辽宁依生生物制药有限公司 (YS Biopharma), founded in 2002, is a pioneering biopharmaceutical firm specializing in the development of innovative biotherapeutics for cancers and infectious diseases. Their signature PIKA® immunomodulating technology sets them apart in the industry, enhancing both innate and adaptive immune responses via the TLR3, RIG-I, and MDA5 pathways.
Their current clinical development products, including YS-ON-001 for treating advanced solid tumors, YS-HBV-001 hepatitis B vaccine, and the PIKA rabies vaccine, demonstrate the company's commitment to addressing critical medical needs.
Recently, the company received a significant $40.00M in post-IPO equity investment, demonstrating strong investor confidence in their endeavors. This investment, received on 09 February 2024, signifies a pivotal moment for 辽宁依生生物制药有限公司(YS Biopharma) as they continue to make strides in the biopharma, biotechnology, and health care industries.
HilleVax